Profile data is unavailable for this security.
About the company
Haemato AG, previously Windsor AG, is a Germany-based pharmaceutical company. The Company trades and patent-free and patent-protected medicines and generic drugs with focus on oncology, human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS), neurology, rheumatology, urology, cardiovascular diseases and other chronic diseases. The Company's main markets are Europe, North America and Japan. It also imports medicines from within the European Economic Area in form of parallel imports and re-imports. The Company's subsidiaries are Haemato Pharm GmbH, Heamato Med GmbH, Castell Pharma BV, Sanate GmbH and Heamato Asia Co Ltd. Customers can order medicine through phone, fax and e-mail, among others.
- Revenue in EUR (TTM)260.81m
- Net income in EUR9.61m
- Incorporated2003
- Employees78.00
- LocationHaemato AGLilienthalstrasse 3aSCHOENEFELD 12529GermanyDEU
- Phone+49 30 897308670
- Fax+49 30 897308679
- Websitehttps://haemato.ag/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I-Mab ADR | -89.58bn | -89.58bn | 76.80m | 220.00 | -- | 0.3958 | -- | -- | -- | -- | -- | 2.91 | -- | -- | -- | -- | -- | -35.51 | -- | -41.43 | -- | -- | -- | -509.54 | -- | -- | 0.00 | -- | 111.86 | -13.65 | 44.45 | -- | -5.95 | -- |
| Sakar Healthcare Ltd | 16.64m | 1.20m | 77.63m | 325.00 | 60.96 | -- | 24.33 | 4.67 | 5.20 | 5.20 | 71.95 | -- | -- | -- | -- | 4,784,942.00 | -- | 5.26 | -- | 6.28 | 45.62 | 43.47 | 7.22 | 10.12 | -- | 3.10 | -- | -- | 14.99 | 17.58 | -8.53 | 11.76 | 19.05 | -- |
| ReproCell Inc | 15.69m | -1.13m | 78.20m | 96.00 | -- | 1.35 | -- | 4.99 | -2.03 | -2.03 | 28.72 | 93.57 | 0.2826 | 4.76 | 6.63 | 25,940,160.00 | -2.03 | -7.35 | -2.20 | -8.00 | 48.99 | 39.83 | -7.18 | -27.16 | 9.99 | -- | 0.00 | -- | -17.83 | 17.39 | 89.71 | -- | 13.27 | -- |
| Zhong Yuan Bio-Technology Holdings Ltd | 2.23m | 207.84k | 79.03m | 35.00 | 391.37 | 348.44 | -- | 35.38 | 0.0128 | -0.0176 | 0.1395 | 0.0143 | 0.8583 | -1.61 | 3.25 | 71,253.43 | 6.49 | -- | 19.10 | -- | 106.30 | -- | 7.57 | -- | 0.8309 | 2.53 | 0.8593 | -- | -28.60 | -- | -148.37 | -- | -- | -- |
| Lee's Pharmaceutical Holdings Ltd | 138.20m | 7.27m | 79.20m | 993.00 | 11.11 | 0.4089 | 3.50 | 0.5731 | 0.1071 | 0.1071 | 2.04 | 2.91 | 0.4403 | 2.11 | 9.70 | 1,134,410.00 | 1.98 | 13.33 | 2.52 | 17.76 | 51.49 | 61.92 | 4.50 | 36.20 | 0.7425 | 6.58 | 0.132 | 3.59 | -14.61 | -1.53 | -67.44 | -47.49 | -12.19 | -31.34 |
| RaQualia Pharma Inc | 14.48m | -4.24m | 79.21m | 67.00 | -- | 2.13 | -- | 5.47 | -31.12 | -31.12 | 106.28 | 261.02 | 0.2652 | 3.82 | 2.89 | 34,300,980.00 | -7.77 | 2.13 | -8.56 | 2.26 | 84.78 | 88.49 | -29.28 | 5.32 | 3.55 | -- | 0.3972 | 0.00 | -34.85 | 20.62 | -144.74 | -- | 0.0967 | -- |
| Haemato AG | 260.81m | 9.61m | 79.90m | 78.00 | 8.36 | 0.5371 | 7.42 | 0.3064 | 1.84 | 1.84 | 50.10 | 28.67 | 1.47 | 9.80 | 12.48 | 3,343,690.00 | 5.41 | 2.01 | 6.45 | 2.70 | 7.56 | 8.42 | 3.68 | 1.21 | 1.66 | -- | 0.0203 | 157.20 | -12.95 | -3.03 | 25.39 | 3.32 | -5.75 | -16.74 |
| Dali Pharmaceutical Co Ltd | 7.04m | -2.73m | 81.01m | 272.00 | -- | 1.73 | -- | 11.51 | -0.0974 | -0.0974 | 0.2508 | 1.68 | 0.1188 | 1.12 | 14.91 | 202,608.50 | -4.61 | -2.31 | -5.40 | -2.77 | 11.07 | 65.39 | -38.84 | -7.00 | 2.74 | -- | 0.0515 | -- | -34.06 | -26.30 | -13.16 | -- | 16.34 | -- |
| EZZ Life Science Holdings Ltd | 41.08m | 4.31m | 81.69m | -- | 25.14 | 8.41 | 17.96 | 1.99 | 0.1607 | 0.1607 | 1.54 | 0.4801 | 3.08 | 13.79 | 33.30 | -- | 32.25 | 24.12 | 38.61 | 31.19 | 76.67 | 65.40 | 10.48 | 9.81 | 5.63 | 482.42 | 0.0058 | -- | 78.88 | 42.81 | 91.87 | 53.25 | 176.34 | -- |
| Oncolys Biopharma Inc | 197.71k | -11.49m | 82.94m | 34.00 | -- | 8.44 | -- | 419.53 | -95.02 | -95.02 | 1.62 | 67.90 | 0.0167 | 0.00 | 0.2245 | 923,058.80 | -97.25 | -45.75 | -116.54 | -51.86 | 0.00 | 60.46 | -5,813.82 | -233.66 | 7.01 | -- | 0.2052 | -- | -93.54 | -17.86 | -68.72 | -- | 28.18 | -- |
| Biosyent Inc | 22.42m | 4.74m | 83.02m | 0.00 | 18.37 | 3.60 | 16.44 | 3.70 | 0.5988 | 0.5988 | 2.83 | 3.06 | 0.8352 | 1.34 | 7.74 | -- | 17.66 | 14.77 | 20.16 | 16.92 | 79.77 | 79.74 | 21.14 | 19.99 | 4.90 | -- | 0.0309 | 9.26 | 13.12 | 7.97 | 18.35 | 2.52 | -2.67 | -- |
Data as of Sep 30 2024. Currency figures normalised to Haemato AG's reporting currency: Euro EUR
0.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Universal-Investment-Gesellschaft mbH (Invt Mgmt)as of 31 Mar 2024 | 0.00 | 0.00% |
| Do Investment AGas of 31 Dec 2023 | 0.00 | 0.00% |
Data from 31 Dec 2023 - 31 Jul 2024Source: FactSet Research Systems Inc.
